เชิงอรรถและอ้างอิง ของ ริสเพอริโดน

  1. 1 2 3 4 5 6 7 8 9 10 "Risperidone". The American Society of Health-System Pharmacists. สืบค้นเมื่อ 2015-12-01.
  2. 1 2 3 4 Hamilton, Richart (2015). Tarascon Pocket Pharmacopoeia 2015 Deluxe Lab-Coat Edition. Jones & Bartlett Learning. pp. 434–435. ISBN 9781284057560.
  3. ↑ Hasnain, M; Vieweg, WV; Hollett, B (2012-07). "Weight gain and glucose dysregulation with second-generation antipsychotics and antidepressants: a review for primary care physicians". Postgraduate Medicine. 124 (4): 154–67. doi:10.3810/pgm.2012.07.2577. PMID 22913904. Check date values in: |date= (help)CS1 maint: uses authors parameter (link)
  4. ↑ Schatzberg, Alan F; Nemeroff, Charles B, eds. (2009). The American Psychiatric Publishing textbook of psychopharmacology (4th ed.). Washington, D.C.: American Psychiatric Pub. p. 627. ISBN 9781585623099.CS1 maint: uses editors parameter (link)
  5. ↑ "WHO Model List of EssentialMedicines" (PDF). World Health Organization. 2013-10. สืบค้นเมื่อ 2014-04-22. Check date values in: |date= (help)
  6. ↑ "Risperidone". International Drug Price Indicator Guide. สืบค้นเมื่อ 2015-12-02.
  7. ↑ "Respiridone". The American Society of Health-System Pharmacists. สืบค้นเมื่อ 2011-04-03.
  8. ↑ Leucht, S; Cipriani, A; Spineli, L และคณะ (2013-09). "Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis". Lancet. 382 (9896): 951–62. doi:10.1016/S0140-6736(13)60733-3. PMID 23810019. Check date values in: |date= (help); Explicit use of et al. in: |authors= (help)CS1 maint: uses authors parameter (link)
  9. ↑ Osser, DN; Roudsari, MJ; Manschreck, T (2013). "The psychopharmacology algorithm project at the Harvard South Shore Program: an update on schizophrenia". Harv Rev Psychiatry. 21 (1): 18–40. doi:10.1097/HRP.0b013e31827fd915. PMID 23656760.CS1 maint: uses authors parameter (link)
  10. ↑ Barry, SJ; Gaughan, TM; Hunter, R (2012). "Schizophrenia". Clin Evid (Online). 2012. PMC 3385413. PMID 23870705.CS1 maint: uses authors parameter (link)
  11. ↑ Glick, ID; Correll, CU; Altamura, AC และคณะ (2011-12). "Mid-term and long-term efficacy and effectiveness of antipsychotic medications for schizophrenia: a data-driven, personalized clinical approach". J Clin Psychiatry. 72 (12): 1616–27. doi:10.4088/JCP.11r06927. PMID 22244023. Check date values in: |date= (help); Explicit use of et al. in: |authors= (help)CS1 maint: uses authors parameter (link)
  12. ↑ Rattehalli, RD; Jayaram, MB; Smith, M (2010). Rattehalli, Ranganath (ed.). "Risperidone versus placebo for schizophrenia". Cochrane Database Syst Rev (1): CD006918. doi:10.1002/14651858.CD006918. PMID 20091611.CS1 maint: multiple names: authors list (link)
  13. ↑ Leucht, C; Heres, S; Kane, JM; Kissling, W; Davis, JM; Leucht, S (2011-04). "Oral versus depot antipsychotic drugs for schizophrenia--a critical systematic review and meta-analysis of randomised long-term trials". Schizophr. Res. 127 (1–3): 83–92. doi:10.1016/j.schres.2010.11.020. PMID 21257294. Check date values in: |date= (help)CS1 maint: uses authors parameter (link)
  14. ↑ Lafeuille, MH; Dean, J; Carter, V และคณะ (2014-08). "Systematic review of long-acting injectables versus oral atypical antipsychotics on hospitalization in schizophrenia". Curr Med Res Opin. 30 (8): 1643–55. doi:10.1185/03007995.2014.915211. PMID 24730586. Check date values in: |date= (help); Explicit use of et al. in: |authors= (help)CS1 maint: uses authors parameter (link)
  15. ↑ Nielsen, J; Jensen, SO; Friis, RB; Valentin, JB; Correll, CU (2014-09). "Comparative Effectiveness of Risperidone Long-Acting Injectable vs First-Generation Antipsychotic Long-Acting Injectables in Schizophrenia: Results From a Nationwide, Retrospective Inception Cohort Study". Schizophr Bull. doi:10.1093/schbul/sbu128. PMID 25180312. Check date values in: |date= (help)CS1 maint: uses authors parameter (link)
  16. ↑ Muralidharan, K; Ali, M; Silveira, LE และคณะ (2013-09). "Efficacy of second generation antipsychotics in treating acute mixed episodes in bipolar disorder: a meta-analysis of placebo-controlled trials". J Affect Disord. 150 (2): 408–14. doi:10.1016/j.jad.2013.04.032. PMID 23735211. Check date values in: |date= (help); Explicit use of et al. in: |authors= (help)CS1 maint: uses authors parameter (link)
  17. ↑ Nivoli, AM; Murru, A; Goikolea, JM และคณะ (2012-10). "New treatment guidelines for acute bipolar mania: a critical review". J Affect Disord. 140 (2): 125–41. doi:10.1016/j.jad.2011.10.015. PMID 22100133. Check date values in: |date= (help); Explicit use of et al. in: |authors= (help)CS1 maint: uses authors parameter (link)
  18. ↑ Yildiz, A; Vieta, E; Leucht, S; Baldessarini, RJ (2011-01). "Efficacy of antimanic treatments: meta-analysis of randomized, controlled trials". Neuropsychopharmacology. 36 (2): 375–89. doi:10.1038/npp.2010.192. PMC 3055677. PMID 20980991. Check date values in: |date= (help)CS1 maint: uses authors parameter (link)
  19. ↑ Peruzzolo, TL; Tramontina, S; Rohde, LA; Zeni, CP (2013). "Pharmacotherapy of bipolar disorder in children and adolescents: an update". Rev Bras Psiquiatr. 35 (4): 393–405. doi:10.1590/1516-4446-2012-0999. PMID 24402215.CS1 maint: uses authors parameter (link)
  20. ↑ Gitlin, M; Frye, MA (2012-05). "Maintenance therapies in bipolar disorders". Bipolar Disord. 14 Suppl 2: 51–65. doi:10.1111/j.1399-5618.2012.00992.x. PMID 22510036. Check date values in: |date= (help)CS1 maint: uses authors parameter (link)
  21. ↑ Gigante, AD; Lafer, B; Yatham, LN (2012-05). "Long-acting injectable antipsychotics for the maintenance treatment of bipolar disorder". CNS Drugs. 26 (5): 403–20. doi:10.2165/11631310-000000000-00000. PMID 22494448. Check date values in: |date= (help)CS1 maint: uses authors parameter (link)
  22. ↑ Kirino, E (2014). "Efficacy and tolerability of pharmacotherapy options for the treatment of irritability in autistic children". Clin Med Insights Pediatr. 8: 17–30. doi:10.4137/CMPed.S8304. PMC 4051788. PMID 24932108.
  23. 1 2 3 "www.janssenpharmaceuticalsinc.com" (PDF).
  24. ↑ Sharma, A; Shaw, SR (2012). "Efficacy of risperidone in managing maladaptive behaviors for children with autistic spectrum disorder: a meta-analysis". J Pediatr Health Care. 26 (4): 291–9. doi:10.1016/j.pedhc.2011.02.008. PMID 22726714.CS1 maint: uses authors parameter (link)
  25. ↑ McPheeters, ML; Warren, Z; Sathe, N และคณะ (2011-05). "A systematic review of medical treatments for children with autism spectrum disorders". Pediatrics. 127 (5): e1312-21. doi:10.1542/peds.2011-0427. PMID 21464191. Check date values in: |date= (help); Explicit use of et al. in: |authors= (help)CS1 maint: uses authors parameter (link)
  26. ↑ Dove, D; Warren, Z; McPheeters, ML; Taylor, JL; Sathe, NA; Veenstra-VanderWeele, J (2012-10). "Medications for adolescents and young adults with autism spectrum disorders: a systematic review". Pediatrics. 130 (4): 717–26. doi:10.1542/peds.2012-0683. PMC 4074627. PMID 23008452. Check date values in: |date= (help)CS1 maint: uses authors parameter (link)
  27. ↑ Taylor, D; Carol, P; Shitij, K (2012). The Maudsley prescribing guidelines in psychiatry. West Sussex: Wiley-Blackwell. ISBN 978-0-470-97969-3.
  28. ↑ Dold, M; Aigner, M; Lanzenberger, R; Kasper, S (2013-04). "Antipsychotic augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: a meta-analysis of double-blind, randomized, placebo-controlled trials". International Journal of Neuropsychopharmacology. 16 (3). doi:10.1017/S1461145712000740. PMID 22932229. Check date values in: |date= (help)CS1 maint: uses authors parameter (link)
  29. 1 2 Maher, AR; Theodore, G (2012-06). "Summary of the comparative effectiveness review on off-label use of atypical antipsychotics". J Manag Care Pharm. 18 (5 Suppl B): S1-20. PMID 22784311. Check date values in: |date= (help)CS1 maint: uses authors parameter (link)
  30. 1 2 3 4 "Risperdal Prescribing Information Label" (PDF). Drugs@FDA: FDA Approved Drug Products. Jannsen Pharmaceuticals, Inc. สืบค้นเมื่อ 2014-04-17.
  31. ↑ Karki, SD; Masood, GR (2003). "Combination risperidone and SSRI-induced serotonin syndrome". Ann Pharmacother. 37 (3): 388–91. doi:10.1345/aph.1C228. PMID 12639169.CS1 maint: uses authors parameter (link)
  32. ↑ BMJ Group, ed. (2009-03). "4.2.1". British National Formulary (57 ed.). United Kingdom: Royal Pharmaceutical Society of Great Britain. p. 192. ISSN 0260-535X. Withdrawal of antipsychotic drugs after long-term therapy should always be gradual and closely monitored to avoid the risk of acute withdrawal syndromes or rapid relapse. Check date values in: |date= (help)
  33. ↑ Chouinard, G; Jones, BD (1980). "Neuroleptic-induced supersensitivity psychosis: clinical and pharmacologic characteristics". Am J Psychiatry. 137 (1): 16–21. PMID 6101522.CS1 maint: uses authors parameter (link)
  34. ↑ Miller, R; Chouinard, G (1993-11). "Loss of striatal cholinergic neurons as a basis for tardive and L-dopa-induced dyskinesias, neuroleptic-induced supersensitivity psychosis and refractory schizophrenia". Biol Psychiatry. 34 (10): 713–38. doi:10.1016/0006-3223(93)90044-E. PMID 7904833. Check date values in: |date= (help)CS1 maint: uses authors parameter (link)
  35. ↑ Chouinard, G; Jones, BD; Annable, L (1978-11). "Neuroleptic-induced supersensitivity psychosis". Am J Psychiatry. 135 (11): 1409–10. PMID 30291. Check date values in: |date= (help)CS1 maint: uses authors parameter (link)
  36. ↑ Seeman, P; Weinshenker, D; Quirion, R; Srivastava, LK; Bhardwaj, SK; Grandy, DK; Premont, RT; Sotnikova, TD; Boksa, P; El-Ghundi, M; O'dowd, BF; George, SR; Perreault, ML; Männistö, PT; Robinson, S; Palmiter, RD; Tallerico, T (2005-03). "Dopamine supersensitivity correlates with D2High states, implying many paths to psychosis". Proc Natl Acad Sci U S A. 102 (9): 3513–8. doi:10.1073/pnas.0409766102. PMC 548961. PMID 15716360. Check date values in: |date= (help)CS1 maint: uses authors parameter (link)
  37. ↑ Moncrieff, J (2006-07). "Does antipsychotic withdrawal provoke psychosis? Review of the literature on rapid onset psychosis (supersensitivity psychosis) and withdrawal-related relapse". Acta Psychiatr Scand. 114 (1): 3–13. doi:10.1111/j.1600-0447.2006.00787.x. PMID 16774655. Check date values in: |date= (help)
  38. ↑ "Risperdal [Package Insert]" (PDF). Titusville, NJ: Janssen Pharmaceuticals. 2014-04. สืบค้นเมื่อ 2014-11-02. Check date values in: |date= (help)
  39. ↑ "Paliperidone". The DrugBank database. 2016-10-16 (updated). Check date values in: |date= (help)
  40. 1 2 3 4 Brunton, L; Chabner, B; Knollman, B (2010). Goodman and Gilman’s The Pharmacological Basis of Therapeutics (12th ed.). McGraw Hill Professional.CS1 maint: uses authors parameter (link)
  41. ↑ RM, Abou El-Magd; Park, HK; Kawazoe, T; Iwana, S; Ono, K; Chung, SP; Miyano, M; Yorita, K; Sakai, T; Fukui, K (2010-07). "The effect of risperidone on D-amino acid oxidase activity as a hypothesis for a novel mechanism of action in the treatment of schizophrenia". Journal of Psychopharmacology. 24 (7): 1055–1067. doi:10.1177/0269881109102644. PMID 19329549. Check date values in: |date= (help)CS1 maint: uses authors parameter (link)
  42. ↑ Hecht, EM; Landy, DC (2012). "Alpha-2 receptor antagonist add-on therapy in the treatment of schizophrenia; a meta-analysis". Schizophrenia Research. 134 (2–3): 202–6. doi:10.1016/j.schres.2011.11.030. PMID 22169246.CS1 maint: uses authors parameter (link)
  43. ↑ National Institute ofMental Health. PDSD Ki Database (Internet) [cited 2013 Aug 10]. ChapelHill (NC) : University of North Carolina. 1998-2013. Available from: http://pdsp.med.unc.edu/pdsp.php
  44. ↑ Smith, C.; Rahman, T.; Toohey, N.; Mazurkiewicz, J.; Herrick-Davis, K.; Teitler, M. (2006). "Risperidone Irreversibly Binds to and Inactivates the h5-HT7 Serotonin Receptor". Molecular Pharmacology. 70 (4): 1264–1270. doi:10.1124/mol.106.024612. ISSN 0026-895X. PMID 16870886.
  45. ↑ "Electronic Orange Book". Food and Drug Administration. 2007-04. สืบค้นเมื่อ 2007-05-24. Check date values in: |date= (help)
  46. ↑ "FDA approves the first drug to treat irritability associated with autism, Risperdal" (Press release). FDA. 2006-10-06. สืบค้นเมื่อ 2009-08-14.
  47. ↑ Scahill, L (2008). "How do I decide whether or not to use medication for my child with autism? should I try behavior therapy first?". J Autism Dev Disord. 38 (6): 1197–8. doi:10.1007/s10803-008-0573-7. PMID 18463973.
  48. 1 2 Drugs.com International trade names for risperidone Page accessed March 15, 2016
  49. ↑ "Companies belittled risks of Risperdal, slapped with huge fine". Los Angeles Times. 2012-04-11.
  50. ↑ "Arkansas Court Reverses $1.2 Billion Judgment Against Johnson & Johnson". NY Times. 2014-03-21.
  51. ↑ "Johnson & Johnson to Pay More Than $2.2 Billion to Resolve Criminal and Civil Investigations | OPA | Department of Justice". Department of Justice. 2013-11-04.
  52. ↑ "NY AG: Janssen pays $181M over drug marketing". The Seattle Times. 2012-08-30.

แหล่งที่มา

WikiPedia: ริสเพอริโดน http://www.drugbank.ca/drugs/DB01267 http://www.biologicalpsychiatryjournal.com/article... http://www.chemspider.com/Chemical-Structure.4895.... http://www.drugs.com/international/risperidone.htm... http://www.drugs.com/monograph/risperidone.html http://www.janssenpharmaceuticalsinc.com/assets/ri... http://www.latimes.com/news/nation/nationnow/la-na... http://www.nytimes.com/2014/03/21/business/arkansa... http://www.sciencedirect.com/science/article/pii/S... http://www.seattletimes.com/seattle-news/ny-ag-jan...